Subsequent development of small-molecule Trk inhibitors has led to breakthrough clinical studies in Trk-fused gene-positive pediatric and adult cancers, which have reported profound durable responses to the Trk inhibitors larotrectinib and entrectinib [10,11]. The gene discussed is NTRK1; the disease is cancer.